Graduate Student Directory

---

Bio

---

Education:

• M.S., Clinical Pharmacy - Jordan University of Science and Technology, 2020

---

Research Areas:

• Experimental Therapeutics repurposing
• Drug development
• Identification of novel therapeutic targets devoted to finding therapies for Alzheimer’s disease

---

Amer Al Khalifa has completed his bachelor’s degree in Pharmacy. His undergraduate study has inspired him to pursue my graduate studies. He finished his Master’s degree in Clinical Pharmacy, from Jordan University of Science and Technology (JUST), Irbid, Jordan. Upon graduation, Al khalifa got a scholarship at the university of Saarland-Germany- faculty of Medicine-2021.

Recently started his research journey as a Ph.D. student in Dr. Kaddoumi’s lab. His research focuses on drug discovery development in the field of neuropharmacology and brain research, to target the blood-brain barrier function as a novel approach to Halt, slow down and/or treat Alzheimer’s disease.

Publications

• A Shatnawi, NM Ayoub, AE Alkhalifa, DR Ibrahim Estrogen-Related Receptors Gene Expression and Copy Number Alteration Association With the Clinicopathologic Characteristics of Breast Cancer, Breast cancer: basic and clinical research 16, 11782234221086713.
• NM Ayoub, SK Jaradat, KM Al-Shami, AE Alkhalifa Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches, Frontiers in Pharmacology 13.
• Ayoub NM, Alkhalifa AE, Ibrahim DR, Alhusban A. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of hormone-dependent breast cancer cells mediated by downregulation of MET and estrogen receptor levels. Med Oncol. 2021 Jan 15;38(1):8. doi: 10.1007/s12032-021-01458-1.
•  Shatnawi A, Ayoub NM, Alkhalifa AE, ING4 Expression Landscape and Association with Clinicopathologic Characteristics in Breast Cancer. Clinical breast cancer (2020). https://doi.org/10.1016/j.clbc.2020.11.011
• Ayoub NM, Ibrahim DR, Alkhalifa AE, Al-Husein B. Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels. Invest New Drugs (2020). https://doi.org/10.1007/s10637- 020-00989-0.
• Al-Shar'i NA, Al-Balas QA, Al-Waqfi RA, Hassan MA, Alkhalifa AE, Ayoub NM. Discovery of a nanomolar inhibitor of the human glyoxalase- I enzyme using structure-based poly- pharmacophore modelling and molecular docking. J Comput Aided Mol Des. 2019 Sep;33(9):799-815.
• Ayoub NM, Ibrahim DR, Alkhalifa AE, Overcoming resistance to targeted therapies using MET inhibitors in solid cancers: Evidence from preclinical and clinical studies. medical oncology (2021) . https://doi.org/10.1007/s12032-021.